Multiple studies have illuminated mechanisms contributing to cancer treatment resistance and progression. Research from Garvan Institute identified suppression of JNK pathway driving estrogen receptor-positive breast cancer resistance. Investigations into METTL16 revealed epigenetic links to non-small cell lung cancer tyrosine kinase inhibitor resistance. Additionally, c-Abl inhibition shown to impair glioma cell growth, while TOPK kinase emerged as a promising prognostic and immunotherapy target in kidney cancer. These advances open avenues for novel precision oncology therapies.